Abstract：
OBJECTIVE: 106Ru eye plaque brachytherapy (BT, interventional radiotherapy) is an eye-preserving treatment for uveal melanoma performed in about 100 clinics worldwide. Despite this relatively low number, there is a considerable variation in clinical practice. In 2022, the BRAPHYQS and Head & Neck and Skin GEC-ESTRO working groups conducted a survey to map the current clinical practice. The survey consisted of a physicist and a physician part. This paper describes the physicist results. However, three physician questions with overlapping interest are included here as well.
METHODS: The survey questions pertained to commissioning and quality control (QC) of the plaques, treatment planning, radiobiological correction, as well as more general questions on practice improvement. The questions overlapping with the physician survey were related to dose prescription and margins.
RESULTS: Sixty-five physicist responses were included. A majority of the centres do not perform an independent measurement of the absorbed dose at reference depth, percentage depth dose (PDD) and off-axis data. A lack of calibration services and suitable equipment are the main reasons. About one third of the centres indicated that they do image based treatment planning. The use of margins and dose prescription showed a large variability, despite the availability of guidelines [1]. Many respondents expressed a strong wish for improvement in a wide range of aspects of clinical practice.
CONCLUSIONS: The physics survey showed a wide variability regarding quality control of the 106Ru sources and treatment planning practice.
METHODS: The survey questions pertained to commissioning and quality control (QC) of the plaques, treatment planning, radiobiological correction, as well as more general questions on practice improvement. The questions overlapping with the physician survey were related to dose prescription and margins.
RESULTS: Sixty-five physicist responses were included. A majority of the centres do not perform an independent measurement of the absorbed dose at reference depth, percentage depth dose (PDD) and off-axis data. A lack of calibration services and suitable equipment are the main reasons. About one third of the centres indicated that they do image based treatment planning. The use of margins and dose prescription showed a large variability, despite the availability of guidelines [1]. Many respondents expressed a strong wish for improvement in a wide range of aspects of clinical practice.
CONCLUSIONS: The physics survey showed a wide variability regarding quality control of the 106Ru sources and treatment planning practice.
摘要：
目的：106Ru眼斑近距离放射治疗（BT，介入性放射疗法）是全球约100家诊所对葡萄膜黑色素瘤进行的一种保留眼睛的治疗方法。尽管这个数字相对较低，在临床实践中有相当大的差异。2022年，BRAPHYQS和头颈部和皮肤GEC-ESTRO工作组进行了一项调查，以绘制当前的临床实践图。调查由物理学家和医生组成。本文描述了物理学家的结果。然而,本文还包括三个兴趣重叠的医师问题.
方法：与试车和板的质量控制（QC）有关的调查问题，治疗计划,放射生物学校正，以及关于实践改进的更一般的问题。与医生调查重叠的问题与剂量处方和边缘有关。
结果：包括65个物理学家的反应。大多数中心在参考深度不进行吸收剂量的独立测量，深度剂量百分比(PDD)和离轴数据。缺乏校准服务和合适的设备是主要原因。大约三分之一的中心表示他们进行基于图像的治疗计划。使用的边缘和剂量处方显示出很大的变异性，尽管有指导方针[1]。许多受访者表示强烈希望在临床实践的各个方面进行改进。
结论：物理调查显示，在106Ru来源的质量控制和治疗计划实践方面存在很大差异。
方法：与试车和板的质量控制（QC）有关的调查问题，治疗计划,放射生物学校正，以及关于实践改进的更一般的问题。与医生调查重叠的问题与剂量处方和边缘有关。
结果：包括65个物理学家的反应。大多数中心在参考深度不进行吸收剂量的独立测量，深度剂量百分比(PDD)和离轴数据。缺乏校准服务和合适的设备是主要原因。大约三分之一的中心表示他们进行基于图像的治疗计划。使用的边缘和剂量处方显示出很大的变异性，尽管有指导方针[1]。许多受访者表示强烈希望在临床实践的各个方面进行改进。
结论：物理调查显示，在106Ru来源的质量控制和治疗计划实践方面存在很大差异。
